SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Bellevue Global Life Science Investors LLC

(Last)

(First)

(Middle)

10900 NE 4TH STREET, SUITE 2300

(Street)

BELLEVUE

98004

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
02/09/2023

3. Issuer Name and Ticker or Trading Symbol
Bellevue Life Sciences Acquisition Corp. [ BLAC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,725,000⁽¹⁾⁽²⁾⁽³⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)

Explanation of Responses:

1. This Form 3 is being filed by Bellevue Global Life Sciences Investors LLC, the sponsor of the Issuer (the "Sponsor"). Kuk Hyoun Hwang, the Issuer's chief executive officer and director, is the founder and managing partner of Bellevue Capital Management LLC ("Bellevue Capital"), the general partner of our sponsor, and has voting and dispositive power over the shares.

2. Includes up to 225,000 shares subject to forfeiture depending on the extent to which the underwriter's over allotment is exercised, if at all.

3. Includes 680,000 shares of common stock held by the Sponsor which, pursuant to a convertible promissory note in the principal amount of $3,400,000 between the Sponsor and BCM Europe AG, a wholly-owned subsidiary of Bellevue Capital, the Sponsor, at its election or the election of BCM Europe AG on or after the initial public offering the common stock, can transfer the 680,000 shares to BCM Europe AG in satisfaction of the note.

Remarks:

	By: Bellevue Capital Management LLC, Its Manager /s/ Kuk Hyoun Hwang, Managing Member	02/09/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.